21:52 , Jul 13, 2018 |  BioCentury  |  Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
21:23 , Feb 26, 2018 |  BC Extra  |  Company News

Achillion rises on positive opinion for C3G therapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending Orphan Drug designation for ACH-4471 to treat C3 glomerulopathy. Achillion gained $0.46 (15%) to $3.41 on Monday. ACH-4471 is a...
20:35 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Apellis reports 18-month Phase II data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
22:56 , Feb 22, 2018 |  BC Extra  |  Clinical News

Apellis reports 18-month data for GA candidate

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) reported 18-month data from the Phase II FILLY trial to treat geographic atrophy showing that APL-2 for 12 months maintained significant reductions in lesion growth at six months after stopping treatment....
21:41 , Dec 1, 2017 |  BC Week In Review  |  Clinical News

Achillion reports preliminary data from a Phase II trial of ACH-4471 for C3 glomerulopathy

Achillion Pharmaceuticals Inc. (NASAQ:ACHN) said preliminary data from the first 2 patients in a Phase IIa trial to treat complement 3 (C3) glomerulopathy (C3G) showed ACH-4471 reduced albumin-to-creatinine ratio from baseline to day 17 by...
00:30 , Oct 20, 2017 |  BC Week In Review  |  Clinical News

Genentech's lampalizumab misses in Phase III for geographic atrophy due to AMD

In September, the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase III Spectri (GX29185) trial in about 975 patients with geographic atrophy (GA) due to age-related macular degeneration (AMD) showing that...
19:30 , Oct 13, 2017 |  BioCentury  |  Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3. However, differences between study populations and methods and durations of treatment also...
22:03 , Sep 18, 2017 |  BC Extra  |  Company News

Management tracks: Kamada, Vertex, Addex, Achillion

Orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said Deputy CEO and CFO Gil Efron will leave at the end of the year. Chaime Orlev will become CFO, effective Jan. 1, 2018. Orlev was CFO...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue development of JNJ-4178 “in light of...
00:12 , Sep 12, 2017 |  BC Extra  |  Company News

Achillion down after J&J drops HCV compound

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $1.08 (22%) to $3.83 Monday after Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal to develop and commercialize HCV therapies, including triplet therapy JNJ-4178. J&J said it decided to discontinue...